Dolutegravir - SAILING Data Confirms Best in Class Integrase Inhibitor - More Threat to Elvitegravir than Raltegravir
Dolutegravir - SAILING data confirms best in class integrase inhibitor - More threat to Elvitegravir than Raltegravir
Clinical data from PhIII SAILING study announced yesterday demonstrated dolutegravir’s statistically significant superiority as compared to Isentress in treatment experienced HIV patients. The data confirms best in class clinical profile of dolutegravir with once daily advantage amongst integrase inhibitors (Raltegravir, Elvitegravir). MRK’s raltegravir (Isentress) is the only integrase inhibitor on the market (2012 sales $1.3b) and ~90% of its total worldwide sales comes from the treatment experienced patient pool. We forecast ……….The Market Dynamics - once all three Integrase inhibitors are on the market Dolutegravir launch is expected in August 2013 (PDUFA – August 17th-2013) and we expect it to initially grab a share……………
Companies mentioned
GlaxoSmithKline, Pfizer, Merck, Shionogi
Clinical data from PhIII SAILING study announced yesterday demonstrated dolutegravir’s statistically significant superiority as compared to Isentress in treatment experienced HIV patients. The data confirms best in class clinical profile of dolutegravir with once daily advantage amongst integrase inhibitors (Raltegravir, Elvitegravir). MRK’s raltegravir (Isentress) is the only integrase inhibitor on the market (2012 sales $1.3b) and ~90% of its total worldwide sales comes from the treatment experienced patient pool. We forecast ……….The Market Dynamics - once all three Integrase inhibitors are on the market Dolutegravir launch is expected in August 2013 (PDUFA – August 17th-2013) and we expect it to initially grab a share……………
Companies mentioned
GlaxoSmithKline, Pfizer, Merck, Shionogi
More Publications
Competitor Analysis: HIV Small Molecule Therapeutics
US$ 642.00
December 2011
100 pages
Therapeutic Class Report Overview : Hepatitis C Virus Infection
US$ 1,000.00
February 2013
31 pages
GILEAD - Providing the Best Antiviral Treatment Options for HIV and HCV!
US$ 140.00
February 2012
11 pages
